Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Recruiting × Blood Specimen Collection × NET × Clear all

Status

Sponsor Class

Study Type

Observational 1

Sponsor

Cancer Type

Gastrointestinal 44 Thoracic 27 Breast 26 Genitourinary 23 Gynecologic 20 Head & Neck 19 Tumor-Agnostic 14 Lymphoid 14 CNS 14 Sarcoma 11 Other hematologic neoplasm 11 Dermatologic 10 Plasma cell 5 Myeloid 5 Other solid neoplasm 2 Endocrine 2 NET 1

Conditions

Neuroendocrine Tumors 1

Interventions

lutetium Lu 177 dotatate 14 Magnetic Resonance Spectroscopy 8 Everolimus 8 gallium Ga 68 dotatate 5 177Lu-octreotide, DOTA(0)-Tyr(3)- 5 lanreotide 4 Specimen Handling 4 olaparib 3 cabozantinib 3 Somatostatin 3 Nivolumab 3 Lutetium-177 3 Injections 3 Fluorodeoxyglucose F18 3 Cyclophosphamide 3 Capecitabine 3 surufatinib 2 pembrolizumab 2 fludarabine phosphate 2 fludarabine 2 copper dotatate CU-64 2 amino-acid, glucose, and electrolyte solution 2 Temozolomide 2 Sunitinib 2 Octreotide 2 Lutetium 2 Ga(III)-DOTATOC 2 Drug Therapy 2 64Cu-DOTATATE 2 zimberelimab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06430021 2025-02-24

PRO-NEM1

Centre Hospitalier Universitaire Dijon

Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon ⚡